Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 136-143

  Jung, G W ^a   Dover, D C ^b   Salopek, T G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Surveillance and Assessment   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANADA; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CUTANEOUS MALIGNANT MELANOMA; CUTANEOUS MELANOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON MELANOMA SKIN CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; EPIDEMIOLOGY; MELANOMA; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDY; RISK FACTOR; SKIN NEOPLASMS;

ADULT; AGED; ALBERTA; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS;

EID: 84892410576     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12694     Document Type: Article

References (70)

1. Katalinic A, Kunze U, Schafer T,. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol 2003; 149: 1200-6.
2. Jung GW, Metelitsa AI, Dover DC, Salopek TG,. Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007. Br J Dermatol 2010; 163: 146-54.
3. Little EG, Eide MJ,. Update on the current state of melanoma incidence. Dermatol Clin 2012; 30: 355-61.
4. Staples MP, Elwood M, Burton RC, et al,. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust 2006; 184: 6-10.
5. Imai S,. The prognosis of skin carcinoma and malignant melanoma with special reference to their extents as represented in terms of T, N, and M of Union Internationale Contre le Cancer (UICC). J Dermatol 1976; 3: 147-54.
6. Chen JG, Fleischer AB Jr, Smith ED, et al,. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 2001; 27: 1035-8.
7. Stang A, Stausberg J, Boedeker W, et al,. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol 2008; 22: 65-72.
8. Nakamura Y, Nakamura Y, Ishitsuka Y, et al,. Facial nerve morbidity following facial nerve preservation surgery for the treatment of skin cancer of the head and neck. J Eur Acad Dermatol Venereol 2012; 26: 1323-5.
9. Ul-Mulk J, Holmich LR,. Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. Dan Med J 2012; 59: A4441.
10. Roh MR, Shin HJ, Lee SH, Chung KY,. Risk of second cancers after the diagnosis of non-melanoma skin cancer in Korean patients. J Dermatol 2012; 39: 541-4.
11. Krueger H, Williams D,. Burden of malignancy after a primary skin cancer: recurrence, multiple skin cancers and second primary cancers. Can J Public Health 2010; 101: 123-7.
12. Wolff J, Wollina U,. Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol 2000; 14: 479-83.
13. Askling J, Sorensen P, Ekbom A, et al,. Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer? Ann Intern Med 1999; 131: 655-9.
14. Nugent Z, Demers AA, Wiseman MC, et al,. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2584-90.
15. Milán T, Pukkala E, Verkasalo PK, et al,. Subsequent primary cancers after basal-cell carcinoma: a nationwide study in Finland from 1953 to 1995. Int J Cancer 2000; 87: 283-8.
16. Chen J, Ruczinski I, Jorgensen TJ, et al,. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst 2008; 100: 1215-22.
17. Levi F, Randimbison L, Te VC, et al,. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int J Cancer 2008; 123: 2899-901.
18. Grant WB,. A meta-analysis of second cancers after a diagnosis of nonmelanoma skin cancer: additional evidence that solar ultraviolet-B irradiance reduces the risk of internal cancers. J Steroid Biochem Mol Biol 2007; 103: 668-74.
19. de Vries E, Soerjomataram I, Houterman S, et al,. Decreased risk of prostate cancer after skin cancer diagnosis: a protective role of ultraviolet radiation? Am J Epidemiol 2007; 165: 966-72.
20. Gallagher RP, Hill GB, Bajdik CD, et al,. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol 1995; 131: 164-9.
21. Gallagher RP, Hill GB, Bajdik CD, et al,. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131: 157-63.
22. Gandini S, Sera F, Cattaruzza MS, et al,. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005; 41: 45-60.
23. Alberta Health Services. Alberta Cancer Registry: 2009 annual report of cancer statistics. Available at: http://www.albertahealthservices.ca/poph/hi- poph-surv-cancer-alta-cancer-registry-2009.pdf (last accessed 23 October 2013).
24. North American Association of Central Cancer Registries. Canadian registries certified in 2012 for 2009 incidence data. Available at: http://www.naaccr.org/Certification/CANCert2009.aspx (last accessed 23 October 2013).
25. Statistics Canada. Table 051-0001. Estimates of population, by age group and sex for July 1, Canada, provinces and territories. Available at: http://www5.statcan.gc.ca/cansim/pick-choisir?lang=eng&p2=33&id=0510001 (last accessed 23 October 2013).
26. Government of Alberta. Interactive health data application-IHDA. Available at: http://www.ahw.gov.ab.ca/IHDA-Retrieval/ (last accessed 23 October 2013).
27. Rothman K, Greenland S, Lash T,. Modern Epidemiology, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 2008.
28. Breslow N, Day N,. Statistical Methods in Cancer Research. Volume II-the Design and Analysis of Cohort Studies. Oxford: Oxford University Press, 1987.
29. Woodward M,. Epidemiology: Study Design and Data Analysis, 2nd edn. Florida: Chapman and Hall/CRC, 2004.
30. Wheless L, Black J, Alberg AJ,. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2010; 19: 1686-95.
31. Spanogle JP, Clarke CA, Aroner S, Swetter SM,. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010; 62: 757-67.
32. Hwang CY, Chen YJ, Lin MW, et al,. Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: a nationwide cohort study in Taiwan. J Dermatol Sci 2010; 60: 167-72.
33. Bradford PT, Freedman DM, Goldstein AM, Tucker MA,. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010; 146: 265-72.
34. Stracci F, Fabrizi V, D'Alo D, et al,. Risk of multiple primary cancers following melanoma and non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2012; 26: 1384-8.
35. Crocetti E, Carli P,. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev 2004; 13: 33-7.
36. Rivas M, Araya MC, Caba F, et al,. Ultraviolet light exposure influences skin cancer in association with latitude. Oncol Rep 2011; 25: 1153-9.
37. Otley CC,. Non-Hodgkin lymphoma and skin cancer: a dangerous combination. Australas J Dermatol 2006; 47: 231-6.
38. Adami J, Frisch M, Yuen J, et al,. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310: 1491-5.
39. Purtilo DT,. Lymphotropic viruses, Epstein-Barr virus (EBV) and human T-cell lymphotropic virus-I (HTLV-I)/adult T-cell leukemia virus (ATLV), and HTLV-III/human immune deficiency virus (HIV) as etiological agents of malignant lymphoma and immune deficiency. AIDS Res 1986; 2 (Suppl. 1): S1-6.
40. Molho-Pessach V, Lotem M,. Viral carcinogenesis in skin cancer. Curr Probl Dermatol 2007; 35: 39-51.
41. Feng H, Shuda M, Chang Y, Moore PS,. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-100.
42. Zwald FO, Brown M,. Skin cancer in solid organ transplant recipients: advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-61, quiz 262.
43. Knight JS, Tsodikov A, Cibrik DM, et al,. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol 2009; 27: 3354-62.
44. Karagas MR, Tosteson TD, Blum J, et al,. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998; 106 (Suppl. 4): 1047-50.
45. Pearce DC, Dowling K, Sim MR,. Cancer incidence and soil arsenic exposure in a historical gold mining area in Victoria, Australia: a geospatial analysis. J Expo Sci Environ Epidemiol 2012; 22: 248-57.
46. Partanen T, Pukkala E, Vainio H, et al,. Increased incidence of lung and skin cancer in Finnish silicotic patients. J Occup Med 1994; 36: 616-22.
47. Barwad A, Sood S, Gupta N, et al,. Human papilloma virus associated head and neck cancer: a PCR based study. Diagn Cytopathol 2012; 40: 893-7.
48. Furumoto H, Irahara M,. Human papilloma virus (HPV) and cervical cancer. J Med Invest 2002; 49: 124-33.
49. Hemminki K, Jiang Y, Dong C,. Second primary cancers after anogenital, skin, oral, esophageal and rectal cancers: etiological links? Int J Cancer 2001; 93: 294-8.
50. Krueger H, Stuart G, Gallagher R,. HPV and Other Infectious Agents in Cancer: Opportunities for Prevention and Public Health. New York: Oxford University Press, 2010.
51. Iftner A, Klug SJ, Garbe C, et al,. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 2003; 63: 7515-19.
52. Chen TH, Huang CC, Yeh KT, et al,. Human papilloma virus 16 E6 oncoprotein associated with p53 inactivation in colorectal cancer. World J Gastroenterol 2012; 18: 4051-8.
53. Noutsou A, Koffa M, Ergazaki M, et al,. Detection of human papilloma virus (HPV) and K-ras mutations in human lung carcinomas. Int J Oncol 1996; 8: 1089-93.
54. Stanley M,. HPV vaccines: are they the answer? Br Med Bull 2008; 88: 59-74.
55. Vasen HF, Gruis NA, Frants RR, et al,. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-leiden). Int J Cancer 2000; 87: 809-11.
56. Borg A, Sandberg T, Nilsson K, et al,. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000; 92: 1260-6.
57. Lupi O,. Correlations between the sonic hedgehog pathway and basal cell carcinoma. Int J Dermatol 2007; 46: 1113-17.
58. Schneider S, Thurnher D, Kloimstein P, et al,. Expression of the sonic hedgehog pathway in squamous cell carcinoma of the skin and the mucosa of the head and neck. Head Neck 2011; 33: 244-50.
59. Yoshikawa K, Shimada M, Miyamoto H, et al,. Sonic hedgehog relates to colorectal carcinogenesis. J Gastroenterol 2009; 44: 1113-17.
60. Davies H, Bignell G, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
61. Kim TH, Park YJ, Lim JA, et al,. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-73.
62. Tol J, Nagtegaal ID, Punt CJ,. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009; 361: 98-9.
63. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
64. Sala E, Mologni L, Truffa S, et al,. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008; 6: 751-9.
65. Prahallad A, Sun C, Huang S, et al,. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-3.
66. Boone B, Jacobs K, Ferdinande L, et al,. EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol 2011; 38: 492-502.
67. Anforth RM, Blumetti TC, Kefford RF, et al,. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167: 1153-60.
68. Lacouture ME, Duvic M, Hauschild A, et al,. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314-22.
69. Hatzivassiliou G, Song K, Yen I, et al,. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
70. Su F, Viros A, Milagre C, et al,. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.